Literature DB >> 16982827

Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.

Gordon Y C Cheung1, Dorothy Xing, Sandra Prior, Michael J Corbel, Roger Parton, John G Coote.   

Abstract

Four recombinant forms of the cell-invasive adenylate cyclase toxin (CyaA) of Bordetella pertussis were compared for the ability to enhance protection against B. pertussis in mice when coadministered with an acellular pertussis vaccine (ACV). The four forms were as follows: fully functional CyaA, a CyaA form lacking adenylate cyclase enzymatic activity (CyaA*), and the nonacylated forms of these toxins, i.e., proCyaA and proCyaA*, respectively. None of these forms alone conferred significant (P > 0.05) protection against B. pertussis in a murine intranasal challenge model. Mice immunized with ACV alone showed significant (P < 0.05) reductions in bacterial numbers in the lungs after intranasal challenge compared with those for control mice. When administered with ACV, both CyaA and CyaA* further reduced bacterial numbers in the lungs of mice after intranasal challenge compared with those for ACV-immunized mice, but the enhanced protection was only significant (P < 0.05) with CyaA*. Coadministration of CyaA* with ACV caused a significant (P < 0.05) increase in immunoglobulin G2a antibody levels against pertactin compared with those in mice immunized with ACV alone. Spleen cells from mice immunized with ACV plus CyaA* secreted larger amounts of interleukin-5 (IL-5), IL-6, gamma interferon (IFN-gamma), and granulocyte-macrophage colony-stimulating factor (GM-CSF) than did cells from mice immunized with ACV plus CyaA or ACV alone after stimulation in vitro with a mixture of B. pertussis antigens. Spleen cells from mice immunized with ACV plus CyaA* also secreted larger amounts of IFN-gamma and GM-CSF than did cells from mice immunized with CyaA* alone after stimulation in vitro with CyaA*. Macrophages from mice immunized with ACV plus CyaA* produced significantly (P < 0.05) higher levels of nitric oxide than did macrophages from mice immunized with CyaA* alone, ACV alone, or ACV plus CyaA after stimulation in vitro with a mixture of B. pertussis antigens or heat-killed B. pertussis cells. These data suggest that the enhancement of protection provided by CyaA* was due to an augmentation of both Th1 and Th2 immune responses to B. pertussis antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982827      PMCID: PMC1698075          DOI: 10.1128/IAI.01104-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.

Authors:  C Canthaboo; D Xing; X Q Wei; M J Corbel
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Phagocytosis of Bordetella pertussis incubated with convalescent serum.

Authors:  Paula S Mobberley-Schuman; Beverly Connelly; Alison A Weiss
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

Review 3.  The adenylate cyclase toxin from Bordetella pertussis--a novel promising vehicle for antigen delivery to dendritic cells.

Authors:  Marcela Simsova; Peter Sebo; Claude Leclerc
Journal:  Int J Med Microbiol       Date:  2004-04       Impact factor: 3.473

4.  Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells.

Authors:  Pádraig J Ross; Ed C Lavelle; Kingston H G Mills; Aoife P Boyd
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

5.  Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.

Authors:  Julia Macdonald-Fyall; Dorothy Xing; Michael Corbel; Susan Baillie; Roger Parton; John Coote
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

6.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; Timothy R Fouts; George K Lewis
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

8.  GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis.

Authors:  Hang Lu; Zhou Xing; Robert C Brunham
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

9.  Phagocyte impotence caused by an invasive bacterial adenylate cyclase.

Authors:  D L Confer; J W Eaton
Journal:  Science       Date:  1982-09-03       Impact factor: 47.728

10.  Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis.

Authors:  James D Cherry; Dorothy X L Xing; Penny Newland; Kashmira Patel; Ulrich Heininger; Michael J Corbel
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

View more
  23 in total

1.  Pore-formation by adenylate cyclase toxoid activates dendritic cells to prime CD8+ and CD4+ T cells.

Authors:  Martina Svedova; Jiri Masin; Radovan Fiser; Ondrej Cerny; Jakub Tomala; Marina Freudenberg; Ludmila Tuckova; Marek Kovar; Gilles Dadaglio; Irena Adkins; Peter Sebo
Journal:  Immunol Cell Biol       Date:  2015-10-06       Impact factor: 5.126

2.  Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.

Authors:  Eiji Komatsu; Fuminori Yamaguchi; Akio Abe; Alison A Weiss; Mineo Watanabe
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

3.  Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine.

Authors:  Maja Jahnmatz; Margaretha Ljungman; Eva Netterlid; Maria C Jenmalm; Lennart Nilsson; Rigmor Thorstensson
Journal:  Clin Vaccine Immunol       Date:  2014-07-09

4.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

Review 5.  Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools.

Authors:  Nicholas H Carbonetti
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

Review 6.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

7.  Use of a Toxin Neutralization Assay To Characterize the Serologic Response to Adenylate Cyclase Toxin after Infection with Bordetella pertussis.

Authors:  Joshua C Eby; Mary C Gray; Jason M Warfel; Tod J Merkel; Erik L Hewlett
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

8.  Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.

Authors:  Karen Scanlon; Ciaran Skerry; Nicholas Carbonetti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways.

Authors:  Giorgio Fedele; Fabiana Spensieri; Raffaella Palazzo; Maria Nasso; Gordon Yiu Chong Cheung; John Graham Coote; Clara Maria Ausiello
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

10.  Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.

Authors:  Yinghua Xu; Yaying Wang; Yajun Tan; Huajie Zhang; Lijie Wu; Lichan Wang; Qiming Hou; Shumin Zhang
Journal:  BMC Microbiol       Date:  2009-12-29       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.